Clinical trials: Melanoma of Skin
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Malignant Melanoma
Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
The purpose of this research study is to study a type of gene therapy treatment called plasmid electroporation. This type of treatment involves the injection of a gene into some melanoma tumors located near the surface of the…
- Trial name
- NCT00323206
- Testing
- IL-12p DNA, Intratumoral Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer, Melanoma
PD-L1 Expression in Cancer (PECan Study).
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study.
- Trial name
- PECan (NCT04436406)
- Testing
- [99mTc]-NM-01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Multiple Myeloma, Melanoma
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Trial name
- NCT03399448
- Testing
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Metastatic Melanoma, Metastasis to Brain
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal…
- Trial name
- NCT05704933
- Testing
- Nivolumab, Ipilimumab, Nivolumab + Relatlimab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
Pilot Study of IFN α2b for Melanoma Patients
The presence of malignant cells in lymph nodes is a critical parameter in the staging of melanoma cancer patients. Assessment of lymph nodes is currently done by histopathology alone.
- Trial name
- NCT00871533
- Testing
- IFNα2b, PEG- IFNα2b
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pittsburgh
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Basal Cell Carcinoma
Remote Assessment of OCT Scans for BCC Detection
Basal cell carcinoma (BCC) is the most common form of cancer and entails approximately 80% of all cutaneous malignancies. This locally destructive neoplasm is commonly diagnosed by punch biopsy which is considered painful, causes…
- Trial name
- NCT06273709
- Testing
- Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner
- Volunteers
- 120 people
- Sponsor
- Maastricht University Medical Center
Melanoma (Skin)
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00090896
- Testing
- maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Melanoma
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Patients with BRAF V600 mutant advanced melanoma benefit from treatment with a BRAF-inhibitor (e.g. dabrafenib, vemurafenib) and from combination of a BRAF- and MEK-inhibitor (e.g. dabrafenib and trametinib).
- Trial name
- NCT02296996
- Testing
- Dabrafenib + Trametinib
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Universitair Ziekenhuis Brussel
Melanoma
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
- Trial name
- NCT03696069
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 501 people
- Sponsor
- Bristol-Myers Squibb
Melanoma (Skin), Skin Cancer
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma.
- Conditions
- Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
- Trial name
- NCT03543969
- Testing
- Encorafenib, Binimetinib, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Skin Neoplasms
Imatinib Mesylate in Treating Patients With Metastatic Melanoma
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma.
- Trial name
- NCT00027586
- Testing
- Imatinib mesylate (STI571)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma Metastatic, Melanoma Recurrent
Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)
The OTIMAS study is a phase II trial designed to evaluate if the duration of one year of pembrolizumab immunotherapy for advanced metastatic melanoma has equivalent efficacy as the two-year duration of historical controls.
- Conditions
- Melanoma Metastatic, Melanoma Recurrent, Cutaneous Melanoma, Stage IV Melanoma
- Trial name
- OTIMAS (NCT07376317)
- Testing
- Pembrolizumab
- Where
- Brazil
- Volunteers
- 29 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Malignant Melanoma Stage IV
Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib
The purpose of this study is to evaluate the activity of Vemurafenib in combination with Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who recurred while in treatment with Vemurafenib.
- Trial name
- BeyPro1 (NCT01983124)
- Testing
- Fotemustine + Vemurafenib
- Where
- 2 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Paola Queirolo
Malignant Melanoma
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
The purpose of this study is to evaluate a specific cellular immune response in melanoma patients that have been vaccinated with a Melan-A VLP vaccine alone or in combination with different adjuvants.
- Trial name
- NCT00651703
- Testing
- CYT004-MelQbG10 + Montanide, CYT004-MelQbG10 + Montanide + Imiquimod, CYT004-MelQbG10 + Imiquimod
- Where
- 2 sites in Switzerland
- Volunteers
- 21 people
- Sponsor
- Cytos Biotechnology AG
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Estrogen Receptor Negative
- Trial name
- NCT01522820
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Melanoma
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
The purpose of this study is to describe the first-line therapy landscape for patients with advanced melanoma and to describe clinical outcomes and healthcare resource utilization in a subset of treatment-naïve patients who…
- Trial name
- NCT03448497
- Testing
- Non-interventional
- Where
- United Kingdom
- Volunteers
- 333 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Melanoma
Minimal SN Tumor Burden
The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not.
- Trial name
- Minitub (NCT01942603)
- Where
- 22 sites in Belgium, France and 8 more
- Volunteers
- 296 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.